Myelodysplastic syndromes: Clinicopathologic features, pathobiology, and molecular pathogenesis

Archives of Pathology and Laboratory Medicine

Volumn 129, Issue 10, 2005, Pages 1299-1310

  Nishino, Ha Thanh ^a   Chang, Chung Che ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR;

ANGIOGENESIS; APOPTOSIS; CANCER SURVIVAL; CELL CYCLE; CLONAL STEM CELL DISEASE; CYTOGENETICS; CYTOPENIA; DISEASE CLASSIFICATION; DYSPLASIA; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; MOLECULAR BIOLOGY; MULTILINEAGE DYSPLASIA; MYELODYSPLASTIC SYNDROME; ONCOGENE; PATHOGENESIS; PROGNOSIS; REGULATOR GENE; REVIEW; STEM CELL;

CYTOGENETICS; DISEASE PROGRESSION; DNA; HUMANS; MYELODYSPLASTIC SYNDROMES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 26044469886     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Kasper DLM, Fauci ASM, Longo DLM, Braunwald EM, Hauser SLM, Jameson JLM, eds. Harrison's Principles of Internal Medicine. 16th ed. Columbus, Ohio: McGraw-Hill Companies Inc; 2005.
2. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71-86.
3. Haas OA, Gadner H. Pathogenesis, biology, and management of myelodysplastic syndromes in children. Semin Hematol. 1996;33:225-235.
4. Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F. Myelodysplastic syndromes: the pediatric point of view. Haematologica. 1995;80: 268-279.
5. McMullin MF, Chisholm M, Hows JM. Congenital myelodysplasia: a newly described disease entity? Br J Haematol. 1991;79:340-342.
6. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
7. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J. 2000;1:53-66.
8. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms [see comment]. Blood 2002;100: 2292-2302.
9. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
10. Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer. 2004;101:226-241.
11. Cilloni D, Messa F, Carturan S, et al. Myelodysplastic syndromes. Ann N Y Acad Sci. 2004;1028:400-408.
12. Erba HP. Recent progress in the treatment of myelodysplastic syndrome in adult patients. Curr Opin Oncol. 2003;15:1-9.
13. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program). 2002:136-161.
14. Silverman LR. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17:585-594.
15. Leone G, Teofili L, Voso MT, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87:1324-1341.
16. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol. 2003;33:153-160.
17. Boultwood J, Wainscoat JS. Clonality in the myelodysplastic syndromes. Int J Hematol. 2001;73:411-415.
18. Busque L, Gilliland DG. X-inactivation analysis in the 1990s: promise and potential problems. Leukemia. 1998;12:128-135.
19. Raskind WH, Steinmann L, Najfeld V. Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia. 1998;12:108-116.
20. Delforge M, Demuynck H, Verhoef G, et al. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol. 1998;102:486-494.
21. Weimar IS, Bourhis JH, De Gast GC, Gerritsen WR. Clonality in myelodysplastic syndromes. Leuk Lymphoma. 1994;13:215-221.
22. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology, part I: classification, natural history and cell biology of myelodysplasia. Int J Hematol. 1993;57:87-97.
23. Hellstrom-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program). 2000:110-132.
24. Barrett J. Myelodysplastic syndrome and aplastic anemia: diagnostic and conceptual uncertainties. Leuk Res. 2000;24:595-596.
25. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002;137:156-163.
26. Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol. 1996;63:265-278.
27. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-1660.
28. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia. 2000;14:2-8.
29. Hoagland HC. Myelodysplastic(preleukemia) syndromes: the bone marrow factory failure problem. Mayo Clin Proc. 1995;70:673-676; quiz 677.
30. Huh YO, Jilani I, Estey E, et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia. 2002; 16:2249-2252.
31. Kouides PA, Bennett JM. Understanding the myelodysplastic syndromes. Oncologist. 1997;2:389-401.
32. Mufti GJ, Galton DA. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin Haematol. 1986;15:953-971.
33. Parker JE, Mufti GJ. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma. 2000;40:1-24.
34. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96: 3932-3938.
35. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos V, Zoumbos NC. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia. 1999;13:1554-1563.
36. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075-1082.
37. Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res. 1998;22:767-777.
38. Kurotaki H, Tsushima Y, Nagai K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome- derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol. 2000;102:115-123.
39. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 1996; 88:4275-4287.
40. Boudard D, Vasselon C, Bertheas MF, et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol. 2002;70:115-125.
41. Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Practice Clin Haematol. 2004;17:543-557.
42. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1-16.
43. Van den Berghe H, Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet. 1997;94:1-7.
44. Nimer SD, Golde DW. The 5q-abnormality. Blood. 1987;70:1705-1712.
45. Le Beau MM, Espinosa R III, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993;90:5484-5488.
46. Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 1993;259:968-971.
47. Le Beau MM, Espinosa R III, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996;88:1930-1935.
48. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76:1083-1091.
49. Neuman WL, Rubin CM, Rios RB, et al. Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders. Blood. 1992;79:1501-1510.
50. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia. 1994;8:638-641.
51. Yunis JJ, Boot AJ, Mayer MG, Bos JL. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene. 1989;4:609-614.
52. Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998; 12:887-892.
53. Lyons J, Janssen JW, Bartram C, Layton M, Mufti GJ. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood. 1988;71:1707-1712.
54. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 1993;82:590-599.
55. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49: 4682-4689.
56. Hirai H, Ishikawa F. The N-ras oncogene in myelodysplastic syndrome and leukemia. Nippon Ketsueki Gakkai Zasshi. 1988;51:1463-1470.
57. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004;14:628-638.
58. Rettenmier CW, Roussel MF. Differential processing of colony-stimulating factor 1 precursors encoded by two human cDNAs. Mol Cell Biol. 1988;8:5026-5034.
59. Tobal K, Pagliuca A, Bhatt B, Bailey N, Layton DM, Mufti GJ. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 1990;4:486-489.
60. Nienhuis AW, Bunn HF, Turner PH, et al. Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5q- syndrome. Cell. 1985;42:421-428.
61. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci U S A. 1990; 87:1377-1380.
62. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997;90:1403-1409.
63. Aoki E, Uchida T, Ohashi H, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia. 2000;14:586-593.
64. Tien HF, Tang JH, Tsay W, et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148-154.
65. Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G. Interaction of EVI with cAMP-responsive element-binding protein-binding protein (CBP) and p300/ CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in colocalization in nuclear speckles. J Biol Chem. 2001;276:44936-44943.
66. Mitani K. Chromosomal abnormalities and oncogenes. Int J Hematol. 1996;63:81-93.
67. Brooks DJ, Woodward S, Thompson FH, et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer. 1996;74:1518-1525.
68. Ogawa S, Mitani K, Kurokawa M, et al. Abnormal expression of Evi-1 gene: in human leukemias. Human Cell. 1996;9:323-332.
69. Sitailo S, Sood R, Barton K, Nucifora G. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Leukemia. 1999;13:1639-1645.
70. Morishita K, Parganas E, Matsugi T, Ihle JN. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol. 1992;12:183-189.
71. Kreider BL, Orkin SH, Ihle JN. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc Natl Acad Sci U S A. 1993;90:6454-6258.
72. Tanaka T, Mitani K, Kurokawa M, et al. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol Cell Biol. 1995;15:2383-2392.
73. Aktas D, Arno MJ, Rassool F, Mufti GJ. Analysis of CHK2 in patients with myelodysplastic syndromes. Leuk Res. 2002;26:985-987.
74. Hofmann WK, Miller CW, Tsukasaki K, et al. Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res. 2001;25:333-338.
75. Kikukawa M, Aoki N, Sakamoto Y, Mori M. Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis. Am J Pathol. 1999;155:717-721.
76. Poppe B, Vandesompele J, Schoch C, et al. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood. 2004;103:229-235.
77. Voura EB, Billia F, Iscove NN, Hawley RG. Expression mapping of adhesion receptor genes during differentiation of individual hematopoietic precursors. Exp Hematol. 1997;25:1172-1179.
78. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome [see comment]. Leuk Res. 2002;26: 677-686.
79. Allampallam K, Shetty VT, Raza A. Cytokines and MDS. Cancer Treat Res. 2001;108:93-100.
80. Mundle SD, Venugopal P, Cartlidge JD, et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996;88:2640-2647.
81. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 1993;53:4701-4714.
82. Petit PX, Susin SA, Zamzami N, Mignotte B, Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett. 1996;396:7-13.
83. Delia D, Aiello A, Soligo D, et al. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood. 1992;79:1291-1298.
84. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 1993;4:41-47.
85. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 1991;6:1915-1922.
86. Kitagawa M, Yoshida S, Kuwata T, Tanizawa T, Kamiyama R. p53 expression in myeloid cells of myelodysplastic syndrome: association with evolution of overt leukemia. Am J Pathol. 1994;145:338-344.
87. Schott RJ, Morrow LA. Growth factors and angiogenesis. Cardiovasc Res. 1993;27:1155-1161.
88. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398-1401.
89. Estey EH. Modulation of angiogenesis in patients with myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17:623-639.
90. Bertolini F, Mancuso P, Gobbi A, Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol. 2000;28:993-1000.
91. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol. 2000;111:43-51.
92. Talks KL, Harris AL. Current status of antiangiogenic factors. Br J Haematol. 2000;109:477-489.
93. Fox SB, Harris AL. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs. 1997;15:15-28.
94. Korkolopoulou P, Apostolidou E, Pavlopoulos PM, et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 2001;15:1369-1376.
95. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2001;106:170-176.
96. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
97. Zhou J, Mauerer K, Farina L, Gribben JG. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci. 2005;10:1581-1596.
98. Marchetto S, Fournier E, Beslu N, et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia. 1999; 13:1374-1382.
99. Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Crb2 and She in Baf3/ Flt3 cells. J Leukoc Biol. 1999;65:372-380.
100. Lyman SD, Williams DE. Biology and potential clinical applications of flt3 ligand. Curr Opin Hematol. 1995;2:177-181.
101. Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11:1442-1446.
102. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
103. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001; 97:2434-2439.
104. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999; 21:163-167.
105. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet. 1994;3(review issue 1):1487-1495.
106. Schulz WA, Elo JP, Florl AR, et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer. 2002;35:58-65.
107. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 1988;48:1159-1161.
108. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MACE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A. 1996;93:7149-7153.
109. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21:5400-5413.
110. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis. 2004;19: 95-101.
111. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-841.
112. Boldt DH. p21(CIP1/WAF1/SDI1) hypermethylation: an exciting new lead in ALL biology. Blood. 2002;99:2283.
113. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpC island hypermethylation is associated with transcriptional silencing of the p21 (CIP1/WAF1/ SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood. 2002;99:2291-2296.
114. Shen L, Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003;101:4131-4136.
115. Li Y, Nagai H, Ohno T, et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 2002;100:2572-2577.
116. Roman-Gomez J, Castillejo JA, Jimenez A, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol. 2003;21:1472-1479.
117. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood. 2000;95:3208-3213.
118. Marinitch DV, Vorobyev IA, Holmes JA, et al. Hypermethylation of 5′-region of the human calcitonin gene in leukemias: structural features and diagnostic significance. Biochemistry (Mosc). 2004;69:340-349.
119. Dhodapkar M, Grill J, Lust JA. Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes. Leuk Res. 1995;19:719-726.
120. Ihalainen J, Pakkala S, Savolainen ER, Jansson SE, Palotie A. Hypermethylation of the calcitonin gene in the myelodysplastic syndromes. Leukemia. 1993;7:263-267.
121. Ruter B, Wijermans PW, Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol. 2004;80:128-135.
122. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res. 1997;57: 1678-1681.
123. Melki JR, Vincent PC, Clark SJ. Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia. Leukemia. 1999;13:877-883.
124. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59:3730-3740.
125. Ekmekci CG, Gutierrez MI, Siraj AK, Ozbek U, Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol. 2004;77:233-240.
126. Ng HH, Jeppesen P, Bird A. Active repression of methylated genes by the chromosomal protein MBD1. Mol Cell Biol. 2000;20:1394-1406.
127. Ng HH, Zhang Y, Hendrich B, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet. 1999;23:58-61.
128. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 1998;19:187-191.
129. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 1998;18:6538-6547.
130. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 1997;88:471-481.
131. Uchida T, Kinoshita T, Hotta T, Murate T. High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. Leuk Lymphoma. 1998;32: 9-18.
132. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985-2990.
133. Lubbert M. Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes? Leukemia. 2003;17:1762-1764.
134. Reynisdottir I, Massague J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 1997;11:492-503.
135. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
136. Li JM, Nichols MA, Chandrasekharan S, Xiong Y, Wang XF. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem. 1995;270:26750-26753.
137. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994;371:257-261.
138. Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma. 1999;35:437-443.
139. Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol. 1986;136:4487-4495.
140. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-962.
141. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
142. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183-3190.
143. Yamaguchi M, Nadler S, Lee JW, Deeg HJ. Induction of negative regulators of haematopoiesis in human bone marrow cells by HLA-DR cross-linking. Transpl Immunol. 1999;7:159-168.
144. Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res. 2003;27:583-591.
145. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-188.
146. Bogdanovic AD, Jankovic GM, Colovic MD, Trpinac DP, Bumbasirevic VZ. Apoptosis in bone marrow of myelodysplastic syndrome patients. Blood. 1996;87:3064.
147. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20:891-900.
148. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
149. Dar S, Mundle S, Andric T, et al. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol. 1999;62:90-94.
150. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049-2054.
151. Deeg HJ, Beckham C, Loken MR, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma. 2000;37:405-414.
152. Allampallam K, Shetty V, Mundle S, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol. 2002;75: 289-297.
153. Reza S, Dar S, Andric T, et al. Biologic characteristics of 164 patients with myelodysplastic syndromes. Leuk Lymphoma. 1999;33:281-287.
154. Raza A, Mundle S, Shetty V, et al. A paradigm shift in myelodysplastic syndromes. Leukemia. 1996;10:1648-1652.
155. Kayagaki N, Yamaguchi N, Abe M, et al. Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell Immunol. 2002; 219:82-91.
156. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98: 3058-3065.
157. Plasilova M, Zivny J, Jelinek J, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002;16: 67-73.
158. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood. 2002;100:3553-3560.
159. Chen C, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 2004;104:4210-4218.
160. Miyazato A, Ueno S, Ohmine K, et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood. 2001;98:422-427.
161. Pellagatti A, Esoof N, Watkins F, et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol. 2004;125:576-583.
162. Ueda M, Ota J, Yamashita Y, et al. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol. 2003;123: 288-296.
163. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983-992.